GlassScriptPhysician profile
John W Thompson
NPI 1073673984
$1,319.74
in general payments reported to CMS, 2019-2025
11 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $155 · 2021: $200 · 2022: $37.88 · 2023: $189 · 2024: $452 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.70 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $375.71 | 2020-2024 | Aristada, Aristada Initio, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $202.46 | 2023-2025 | Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $154.05 | 2019-2020 | |
| Indivior INC. | $139.51 | 2023-2024 | Perseris |
| Painteq LLC | $120.33 | 2021 | |
| Neurocrine Biosciences, INC. | $102.78 | 2021-2025 | |
| Bioxcel Therapeutics, INC. | $89.79 | 2023-2024 | Igalmi |
| Otsuka America Pharmaceutical, INC. | $82.51 | 2023-2025 | Abilify Maintena, Abilify Asimtufii |
| Bausch & Lomb Americas INC. | $21.18 | 2024 | Vyzulta, Xiidra, Miebo |
| Abbvie INC. | $17.33 | 2023 | Vraylar |
| Sight Sciences, INC. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.